XNAS · Healthcare · Biotechnology
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.11 | -1.08 | -881.82% | $5.7M | ❌ Miss | -1.26% | -20.65% | — |
| 2026-03-16 | Q4 2025 | -0.09 | 0.01 | +111.11% | $21.9M | ✅ Beat | +6.84% | -14.54% | +132.52% |
| 2025-11-12 |
| Q3 2025 |
| -0.09 |
| -0.07 |
| +22.22% |
| $2.1M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.13 | -0.09 | +30.77% | $3.0M | ✅ Beat | -3.54% | +3.29% | -3.08% |
| 2025-03-31 | Q4 2024 | -0.14 | -0.13 | +7.14% | $1.6M | ✅ Beat | -17.67% | -31.31% | -17.11% |
| 2024-11-14 | Q3 2024 | -0.19 | -0.17 | +10.53% | $3.3M | ✅ Beat | -17.00% | -31.33% | -32.00% |
| 2024-08-14 | Q2 2024 | -0.29 | -0.20 | +31.03% | $2.7M | ✅ Beat | -4.21% | +45.98% | -5.00% |
| 2024-04-08 | Q4 2023 | -0.28 | -0.28 | +0.00% | $1.8M | ➖ Inline | -6.86% | -21.81% | -6.37% |
Showing last 8 quarters.